Michael Lukason

1.3k total citations
20 papers, 917 citations indexed

About

Michael Lukason is a scholar working on Molecular Biology, Genetics and Ophthalmology. According to data from OpenAlex, Michael Lukason has authored 20 papers receiving a total of 917 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Genetics and 5 papers in Ophthalmology. Recurrent topics in Michael Lukason's work include Virus-based gene therapy research (9 papers), Retinal Development and Disorders (8 papers) and RNA Interference and Gene Delivery (8 papers). Michael Lukason is often cited by papers focused on Virus-based gene therapy research (9 papers), Retinal Development and Disorders (8 papers) and RNA Interference and Gene Delivery (8 papers). Michael Lukason collaborates with scholars based in United States and Switzerland. Michael Lukason's co-authors include Seng H. Cheng, Abraham Scaria, Elizabeth Barry, Guo-Xiang Ruan, Dan Yu, Ronald K. Scheule, Samuel C. Wadsworth, Jennifer D. Tousignant, Simon J. Eastman and Peter Pecháň and has published in prestigious journals such as Molecular Therapy, Gene Therapy and Human Gene Therapy.

In The Last Decade

Michael Lukason

20 papers receiving 883 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Lukason United States 14 735 387 204 107 97 20 917
Margaret Humphries United States 10 893 1.2× 863 2.2× 128 0.6× 52 0.5× 148 1.5× 15 1.3k
Bruce A. Boswell United States 16 458 0.6× 257 0.7× 92 0.5× 69 0.6× 42 0.4× 20 760
Sharifah Iqball United Kingdom 15 529 0.7× 312 0.8× 124 0.6× 60 0.6× 77 0.8× 27 909
Annahita Keravala United States 18 868 1.2× 324 0.8× 115 0.6× 60 0.6× 48 0.5× 27 1.1k
Thomas W. Chalberg United States 9 900 1.2× 538 1.4× 172 0.8× 166 1.6× 120 1.2× 17 1.1k
Sam Wadsworth United States 11 283 0.4× 192 0.5× 91 0.4× 50 0.5× 47 0.5× 19 546
Ajay Mistry United Kingdom 10 446 0.6× 229 0.6× 125 0.6× 152 1.4× 47 0.5× 16 595
Samuel W. Du United States 12 611 0.8× 231 0.6× 29 0.1× 43 0.4× 51 0.5× 23 1.0k
Carole Bloquel France 14 392 0.5× 171 0.4× 130 0.6× 94 0.9× 32 0.3× 15 802
Jacqueline K. Rainger United Kingdom 7 826 1.1× 184 0.5× 18 0.1× 51 0.5× 101 1.0× 8 1.4k

Countries citing papers authored by Michael Lukason

Since Specialization
Citations

This map shows the geographic impact of Michael Lukason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Lukason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Lukason more than expected).

Fields of papers citing papers by Michael Lukason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Lukason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Lukason. The network helps show where Michael Lukason may publish in the future.

Co-authorship network of co-authors of Michael Lukason

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Lukason. A scholar is included among the top collaborators of Michael Lukason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Lukason. Michael Lukason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Boye, Sanford L., Catherine R. O’Riordan, James Morris, et al.. (2022). Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis. Molecular Therapy — Methods & Clinical Development. 28. 129–145. 4 indexed citations
2.
Sullivan, Jennifer A., Lin Liu, Michael Lukason, et al.. (2020). Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea. Human Gene Therapy. 31(13-14). 756–774. 25 indexed citations
3.
Sullivan, Jennifer A., Lisa M. Stanek, Michael Lukason, et al.. (2018). Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain. Gene Therapy. 25(3). 205–219. 27 indexed citations
4.
Ruan, Guo-Xiang, Elizabeth Barry, Dan Yu, et al.. (2017). CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10. Molecular Therapy. 25(2). 331–341. 212 indexed citations
5.
Sullivan, Jennifer A., Lisa M. Stanek, Michael Lukason, et al.. (2016). 301. AAV Capsid Engineering to Improve Transduction in Retina and Brain. Molecular Therapy. 24. S120–S121. 3 indexed citations
6.
Ruan, Guo-Xiang, Elizabeth Barry, Michael Lukason, Seng H. Cheng, & Abraham Scaria. (2016). 329. Using CRISPR/Cas9 as a Therapeutic Approach for Leber Congenital Amaurosis 10 (LCA10). Molecular Therapy. 24. S131–S132. 14 indexed citations
7.
MacLachlan, Timothy K., Michael Lukason, Margaret E. Collins, et al.. (2010). Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration. Molecular Therapy. 19(2). 326–334. 136 indexed citations
8.
Lukason, Michael, Hillard Rubin, Peter Pecháň, et al.. (2010). Inhibition of Choroidal Neovascularization in a Nonhuman Primate Model by Intravitreal Administration of an AAV2 Vector Expressing a Novel Anti-VEGF Molecule. Molecular Therapy. 19(2). 260–265. 67 indexed citations
9.
Hurlbut, Gregory D, Robin J. Ziegler, Jennifer B. Nietupski, et al.. (2010). Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy. Molecular Therapy. 18(11). 1983–1994. 117 indexed citations
10.
Siders, William, Jacqueline D. Shields, Johanne Kaplan, et al.. (2009). Cytotoxic T Lymphocyte Responses to Transgene Product, Not Adeno-Associated Viral Capsid Protein, Limit Transgene Expression in Mice. Human Gene Therapy. 20(1). 11–20. 17 indexed citations
11.
Pecháň, Peter, Hillard Rubin, Michael Lukason, et al.. (2008). Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Therapy. 16(1). 10–16. 83 indexed citations
12.
Siders, William, Jacqueline D. Shields, Johanne Kaplan, et al.. (2008). Cytotoxic T-Lymphocyte (CTL) responses to the transgene product and not AAV capsid protein limit transgene expression in mice. Human Gene Therapy. 0(ja). 3420089880–3420089880. 3 indexed citations
13.
Scaria, Abraham, Peter Pecháň, Hillard Rubin, et al.. (2006). 883. AAV-2 Based Gene Therapy Using Novel Anti-VEGF Molecules for Inhibition of Angiogenesis in the Eye. Molecular Therapy. 13. S340–S340. 1 indexed citations
14.
Li, Chester, Robin J. Ziegler, Maribeth Cherry, et al.. (2002). Adenovirus-Transduced Lung as a Portal for Delivering α-Galactosidase A into Systemic Circulation for Fabry Disease. Molecular Therapy. 5(6). 745–754. 29 indexed citations
15.
Scaria, Abraham, Jennifer A. Sullivan, Judith A. St. George, et al.. (2000). Adenoviral Vector Expressing ICP47 Inhibits Adenovirus-Specific Cytotoxic T Lymphocytes in Nonhuman Primates. Molecular Therapy. 2(5). 505–514. 10 indexed citations
16.
Eastman, Simon J., et al.. (1998). Aerosolization of Cationic Lipid:pDNA Complexes— In Vitro Optimization of Nebulizer Parameters for Human Clinical Studies. Human Gene Therapy. 9(1). 43–52. 22 indexed citations
17.
McDonald, Ruth J., Michael Lukason, Otto G. Raabe, et al.. (1997). Safety of Airway Gene Transfer with Ad2/CFTR2: Aerosol Administration in the Nonhuman Primate. Human Gene Therapy. 8(4). 411–422. 21 indexed citations
18.
Eastman, Simon J., Michael Lukason, Jennifer D. Tousignant, et al.. (1997). A Concentrated and Stable Aerosol Formulation of Cationic Lipid:DNA Complexes Giving High-Level Gene Expression in Mouse Lung. Human Gene Therapy. 8(6). 765–773. 64 indexed citations
19.
Eastman, Simon J., Jennifer D. Tousignant, Michael Lukason, et al.. (1997). Optimization of Formulations and Conditions for the Aerosol Delivery of Functional Cationic Lipid:DNA Complexes. Human Gene Therapy. 8(3). 313–322. 60 indexed citations
20.
DuBose, David A., Lawrence E. Armstrong, W J Kraemer, & Michael Lukason. (1989). Modulation of human plasma fibronectin levels following exercise.. PubMed. 60(3). 241–5. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Margaret Humphries Breakdown of academic impact, for papers by Bruce A. Boswell Breakdown of academic impact, for papers by Sharifah Iqball Breakdown of academic impact, for papers by Annahita Keravala Breakdown of academic impact, for papers by Thomas W. Chalberg Breakdown of academic impact, for papers by Sam Wadsworth Breakdown of academic impact, for papers by Ajay Mistry Breakdown of academic impact, for papers by Samuel W. Du Breakdown of academic impact, for papers by Carole Bloquel Breakdown of academic impact, for papers by Jacqueline K. Rainger
Rankless by CCL
2026